Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06922188 · ClinicalTrials.gov registry record
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
A clinical trial of Financial Hardship and Alzheimer's Disease (AD), sponsored by Fred Hutchinson Cancer Center.
- Recruiting
- Registry status
- 2,460
- Enrollment target
- 1
- Study location
NCT06922188 is a study of Financial Hardship and Alzheimer's Disease (AD) that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 2,460 participants, above the 184-participant average among 5 other Financial Hardship trials with a reported enrollment target (1237% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06922188, a study of Financial Hardship and Alzheimer's Disease (AD), is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.
- RECRUITING
- Registry status
- 2,460 participants
- Enrollment target
- 1
- Study location
Study Summary
Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work productivity and income for their caregivers that can last for decades after disease onset, and difficulty deciding between nursing home care or home-based care while negotiating insurance coverage. People from historically marginalized groups can experience a double disparity with fewer financial resources to manage AD/ADRD and a greater risk of AD/ADRD. Screening for financial hardship in AD/ADRD is key for addressing the needs of patients and caregivers but critical barriers include a lack of suitable screening measures. Current measures are very general and meant for people without chronic medical conditions or are specific to other diseases. To fill this gap, this study will create a suite of measures that can screen for financial hardship in people with AD/ADRD and their families and caregivers. The measures will include a set to assess caregiver burden; a set to assess patient hardship as reported by the caregiver for patients who cannot report for themselves; and a set of patient-reported measures for patients that are able to report for themselves. To create these financial hardship screening measures, the project will conduct the following aims. Aim 1- Develop financial hardship screening measures for Alzheimer's Disease and related dementias: Using interviews with both caregivers and people with AD/ADRD, key indicators of financial hardship that are unique to AD/ADRD and the point in the lifespan in which it occurs will be identified. The ways that social and caregiver network size affect financial hardship will also be explored. Using the interviews and previous measures, preliminary measures will be created and will be reviewed by experts and a patient and c
Conditions Studied
Study Locations (1)
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,460 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2029-12-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06922188
The ClinicalTrials.gov registry entry for NCT06922188 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,460 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 5 other Financial Hardship trials with a reported enrollment target (1237% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Financial Hardship appearing as the primary indexed condition, and to 0 interventions.
NCT06922188 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06922188 about?
NCT06922188 is a clinical study titled "Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia". Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work...
What is the current status of trial NCT06922188?
This trial is currently recruiting. The enrollment target is 2,460 participants. The study started on 2025-03-31. Estimated completion is 2029-12-18.
What conditions does trial NCT06922188 study?
This clinical trial studies the following conditions: Financial Hardship, Alzheimer's Disease (AD), Alzheimer's Disease and Related Dementia (ADRD).
Who is sponsoring clinical trial NCT06922188?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06922188 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Financial Hardship
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Recovery Finance: Financial Health and Mental Health After Incarceration
RECRUITING · NA
-
PediRISE Feasibility
RECRUITING · NA
-
Guaranteed Income and Financial Treatment
ACTIVE NOT RECRUITING · NA
-
Addressing Financial and Social Needs Among Patients With Cancer
ACTIVE NOT RECRUITING · NA
-
Black Economic Equity Movement
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.